Humacyte, Inc.
HUMAAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Oct 16, 2026 | Williams Trading | $1.00(+124%) | $0.45 | StreetInsider | |
| Aug 12, 2026 | BTIG | Ryan Zimmerman | $2.00(+214%) | $0.64 | StreetInsider |
| Dec 1, 2025 | H.C. Wainwright | Swayampakula Ramakanth | $3.00(+122%) | $1.35 | StreetInsider |
| Oct 13, 2025 | UBS | $6.00(+257%) | $1.68 | TheFly | |
| Aug 27, 2025 | Barclays | Matt Miksic | $3.50(+138%) | $1.47 | TheFly |
| Oct 18, 2024 | Piper Sandler | Matt O'Brien | $6.00(+23%) | $4.86 | StreetInsider |
| Oct 18, 2024 | BTIG | Ryan Zimmerman | $10.00(+106%) | $4.86 | StreetInsider |
| Dec 20, 2022 | Cowen & Co. | Cowen Cowen | $5.00(+127%) | $2.21 | Pulse 2.0 |
| May 15, 2022 | Piper Sandler | Matt O'Brien | $4.00(-26%) | $5.37 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Benchmark | maintain | Speculative Buy | Aug 13, 2026 |
| BTIG | maintain | Buy | Jul 28, 2026 |
| TD Cowen | maintain | Buy | Jun 17, 2026 |
| BTIG | maintain | Buy | Jun 16, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jun 11, 2026 |
| BTIG | maintain | Buy | Jun 8, 2026 |
| Benchmark | maintain | Speculative Buy | Jun 1, 2026 |
| HC Wainwright & Co. | maintain | Buy | May 26, 2026 |
| TD Cowen | maintain | Buy | May 14, 2026 |
| BTIG | maintain | Buy | May 13, 2026 |
| BTIG | maintain | Buy | Apr 28, 2026 |
| D. Boral Capital | maintain | Buy | Apr 28, 2026 |
| D. Boral Capital | maintain | Buy | Apr 24, 2026 |
| D. Boral Capital | maintain | Buy | Apr 21, 2026 |
| Barclays | maintain | Overweight | Apr 8, 2026 |
| Benchmark | maintain | Buy →Speculative Buy | Mar 31, 2026 |
| Piper Sandler | maintain | Neutral | Mar 30, 2026 |
| TD Cowen | maintain | Buy | Mar 30, 2026 |
| BTIG | maintain | Buy | Mar 27, 2026 |
| D. Boral Capital | maintain | Buy | Mar 27, 2026 |
| D. Boral Capital | maintain | Buy | Mar 19, 2026 |
| D. Boral Capital | maintain | Buy | Mar 17, 2026 |
| D. Boral Capital | maintain | Buy | Feb 19, 2026 |
| BTIG | maintain | Buy | Feb 9, 2026 |
| D. Boral Capital | maintain | Buy | Feb 9, 2026 |
Earnings History
| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 12, 2026 | $-0.16 | $-0.11 | $406.0K | $1.0M |
| May 13, 2026 | $-0.09 | $-0.10 | $495.0K | $1.5M |
| Mar 27, 2026 | $-0.13 | $-0.13 | $467.0K | $1.3M |
| Nov 12, 2025 | $-0.14 | $-0.17 | $753.0K | $922.8K |
| Aug 11, 2025 | $-0.24 | $-0.15 | $301.0K | $1.0M |
| May 13, 2025 | $0.28 | $-0.19 | $517.0K | $764.8K |
| Mar 28, 2025 | $-0.16 | $-0.24 | $7.2M | $640.2K |
| Nov 8, 2024 | $-0.33 | $-0.25 | — | $214.3K |
News
The latest trading day saw Humacyte, Inc. (HUMA) settling at $0.4, representing a -12.11% change from its previous close.
– Founder & CEO Laura Niklason, M.D., Ph.D., to deliver invited talk on engineering the microenvironment to accelerate vascular regeneration.
DURHAM, N.C, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the Company will release its financial results for the three months and nine months ended September 30, 2026, on Tuesday, November 10, 2026. Management will host a webcast and conference call at 8:00 a.m. Eastern Time to provide a corporate and financial update.
Humacyte, Inc. (HUMA) concluded the recent trading session at $0.41, signifying a -13.01% move from its prior day's close.
– Patent provides coverage into 2043 for key aspects of how Symvess is manufactured, sterilized, stored and shipped. DURHAM, N.C.
Shares of Humacyte, Inc. (NASDAQ: HUMA - Get Free Report) have received a consensus rating of "Moderate Buy" from the eight research firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have given a buy recommendation to
- The presenter, Dr. Roy-Chaudhury said, “These results give the nephrology community a strong reason to rethink our approach to access decisions for women and, once approved by the FDA, to consider the ATEV as a meaningful new option.”
Humacyte, Inc. (HUMA) closed at $0.41 in the latest trading session, marking a +1.28% move from the prior day.
In the most recent trading session, Humacyte, Inc. (HUMA) closed at $0.4, indicating a -6.5% shift from the previous trading day.
– Hospitals that have ordered Symvess® increased 44% during the third quarter, from 34 at the end of the second quarter to 49 as of September 30, 2026. – Commercial momentum continues to build, driven by expanding hospital orders and surgeon interest.
Humacyte, Inc. (HUMA) concluded the recent trading session at $0.36, signifying a -7.88% move from its prior day's close.
Humacyte, Inc. (HUMA) concluded the recent trading session at $0.48, signifying a -4.26% move from its prior day's close.
Humacyte, Inc. (HUMA) concluded the recent trading session at $0.5, signifying a -2.86% move from its prior day's close.
DURHAM, N.C., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the addition of life science industry veterans Scott Coward and Paul Kuznik to the Company's Board of Directors, both of whom bring substantial experience in the areas of commercialization, enterprise leadership, and global operations.
The latest trading day saw Humacyte, Inc. (HUMA) settling at $0.56, representing a -2% change from its previous close.
Humacyte, Inc. (HUMA) reached $0.59 at the closing of the latest trading day, reflecting a +2.23% change compared to its last close.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that Laura Niklason, M.D.
– FDA authorizes extension of Symvess expiration dating from 18 months to 36 months – – Extended shelf life supported by additional stability data demonstrating Symvess continues to meet all established quality specifications throughout the 36-month dating period – DURHAM, N.C., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology company that develops bioengineered human tissues, today announced that the U.S. Food and Drug Administration (FDA) has a…
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into Humacyte, Inc. (NasdaqGS: HUMA) (“Humacyte” or the “Company”). On August 9, 2024, the company announced that the Food and Drug Administration (“FDA”) “will require additional time to complete its review of its Biologic License Application (BLA) for the acellular tissue engin.